Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
CGTLive®’s Weekly Rewind – September 20, 2024
Review top news and interview highlights from the week ending September 20, 2024.
Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
The product is currently being evaluated in a phase 1/1b clinical trial.
Around the Helix: Cell and Gene Therapy Company Updates – September 18, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Vironexis Biotherapeutics’ AAV Vector-Based Immunotherapy VNX-101 Cleared for US Trial in Acute Lymphoblastic Leukemia
VNX-101 is intended to transduce cells of the liver, causing them to express a transgene coding for a bispecific T-cell engager.
Data Roundup: August 2024 Features Updates in CAR-T, mRNA Therapy, and Gamma Delta T-cell Therapy for Various Cancers
Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.
Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808
The company also discontinued its other clinical programs as well, which included small molecule and monoclonal antibody modalities.